Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2026 04:53 ET | Source: Exact Therapeutics AS

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026...
February 04, 2026 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
February 04, 2026 09:00 ET | Source: American Oncology Network

RKV Medical Center Joins American Oncology Network as First Partner Practice in Oklahoma

RKV Medical Center Joins American Oncology Network as First Partner Practice in Oklahoma
February 02, 2026 10:02 ET | Source: Urology Care Foundation

Keep Life Flowing Smoothly This National Cancer Prevention Month: Your Guide to Taking Action

BALTIMORE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month and to help people keep life flowing smoothly, the Urology Care Foundation (UCF), the official foundation of...
January 29, 2026 12:01 ET | Source: AB Science

AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant

COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN AVIS D'AUTORISATION POUR UN BREVET AMÉRICAIN COUVRANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT CETTE DÉCISION...
January 29, 2026 12:01 ET | Source: AB Science

AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE...
January 29, 2026 09:00 ET | Source: Panakeia Technologies Ltd

Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer

Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer
January 29, 2026 08:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
January 28, 2026 12:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
January 28, 2026 10:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...